Sunday, July 27, 2025
News Health
  • Health News
  • Hair Products
  • Nutrition
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health
No Result
View All Result
  • Health News
  • Hair Products
  • Nutrition
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health
No Result
View All Result
HealthNews
No Result
View All Result
Home Health News

EMA Recommends Aqneursa for Niemann-Pick Type C Disease

July 25, 2025
in Health News
Share on FacebookShare on Twitter


At its July 2025 meeting, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended granting a marketing authorization in the European Union for Aqneursa (IntraBio Ireland Ltd) for the treatment of neurologic manifestations of Niemann-Pick type C (NPC) disease.

The treatment can be used in combination with miglustat, or as a monotherapy for patients in whom miglustat is not tolerated, in adults and children aged 6 years and older and weighing at least 20 kg, the CHMP said.

It also pointed out that miglustat is the only medicine authorized to treat NPC disease and has been shown to slow the general progression of neurologic symptoms in patients.

NPC disease is a rare, progressive, and fatal genetic disorder caused by mutations encoding lysosomal proteins that are essential for the intracellular transport and metabolism of body fats, including cholesterol. Over time, the cells of the central nervous system and the body organs stop working. There are no curative therapies for NPC disease.

The course of the disease varies highly depending on the age of onset, but most patients with NPC disease are children and die before the age of 20. 

Improvement in Neurologic Signs, Symptoms, and Functioning 

The active substance of Aqneursa is levacetylleucine, a modified form of the amino acid leucine that targets underlying processes of neurologic dysfunction. Although the mechanism of action of levacetylleucine is not yet fully understood, nonclinical studies have demonstrated that it corrects energy metabolism. This includes improved production of adenosine triphosphate, the main source of energy for cerebellar tissues and cells.

A randomized, double-blind, placebo-controlled, two-period crossover phase 3 study demonstrated that levacetylleucine offered improvement in neurologic signs, symptoms, and functioning — measured using the Scale for the Assessment and Rating of Ataxia — in patients with NPC disease after 12 weeks of treatment compared with placebo.

For the study, 60 patients aged 4 years or older with a confirmed diagnosis of NPC disease and at least mild disease-related neurologic symptoms were randomized in a 1:1 ratio to receive either levacetylleucine or placebo for 12 weeks. For the second 12 weeks, patients were switched to the opposite: either placebo or levacetylleucine.

At the end of the first 12 weeks, patients treated with levacetylleucine demonstrated a statistically significant improvement compared with those treated with placebo. At the end of the second 12 weeks, patients who switched from levacetylleucine to placebo experienced a significant worsening of symptoms.

The only adverse event causally related to treatment with levacetylleucine is flatulence. The drug will be available as 1-g granules for oral suspension.

Rob Hicks is a retired National Health Service doctor. A well-known TV and radio broadcaster, he has written several books and has regularly contributed to national newspapers, magazines, and online publications. He is based in the United Kingdom.



Source link : https://www.medscape.com/viewarticle/ema-recommends-aqneursa-niemann-pick-type-c-disease-2025a1000jqr?src=rss

Author :

Publish date : 2025-07-25 14:40:00

Copyright for syndicated content belongs to the linked Source.

Previous Post

New Injectable Recommended by Europe for HIV Prevention

Next Post

Nursing Course Applications Hit Record Low, UCAS Reveals

Related Posts

Health News

Why Is HHS Targeting the Organ Transplant System?

July 26, 2025
Health News

RFK Jr. Reportedly Planning to Fire All USPSTF Members

July 26, 2025
Health News

The Rise in Adolescent Bariatric Surgery Doesn’t Mean GLP-1s Have Failed

July 26, 2025
Health News

After Venus Williams’ Comment, Here’s What to Know About Athletes’ Health Insurance

July 26, 2025
Health News

How Running Marathons Helps These Sisters Manage Their Prediabetes

July 26, 2025
Health News

‘My dad started spying on my mum’ – the drugs causing sexual urges

July 26, 2025
Load More

Why Is HHS Targeting the Organ Transplant System?

July 26, 2025

RFK Jr. Reportedly Planning to Fire All USPSTF Members

July 26, 2025

The Rise in Adolescent Bariatric Surgery Doesn’t Mean GLP-1s Have Failed

July 26, 2025

After Venus Williams’ Comment, Here’s What to Know About Athletes’ Health Insurance

July 26, 2025

How Running Marathons Helps These Sisters Manage Their Prediabetes

July 26, 2025

‘My dad started spying on my mum’ – the drugs causing sexual urges

July 26, 2025

10,000 steps myth – should you be a stickler for recommended daily doses?

July 26, 2025

Why we need to talk about periods, breasts and injuries

July 25, 2025
Load More

Categories

Archives

July 2025
MTWTFSS
 123456
78910111213
14151617181920
21222324252627
28293031 
« Jun    

© 2022 NewsHealth.

No Result
View All Result
  • Health News
  • Hair Products
  • Nutrition
    • Weight Loss
  • Sexual Health
  • Skin Care
  • Women’s Health
    • Men’s Health

© 2022 NewsHealth.

Go to mobile version